Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
0.38x
AMBUJACEM's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.
Free Cash Flow
₹-64.50B
AMBUJACEM's free cash flow was negative at ₹-64.50B in FY 2025, down 654.4% from FY 2024. The company spent more on capital investments than it generated from operations.
Dividend Coverage
-11.5x
AMBUJACEM's free cash flow did not fully cover dividends in FY 2025. The company may be funding dividends from reserves or borrowings.
CapEx Intensity
388.3%
Capital expenditure consumed 388.3% of operating cash flow in FY 2025 for AMBUJACEM, typical of capital-intensive industries.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 58.96B | 59.22B | |
| Cash flow Operating Activities | 56.46B | 22.37B | |
| Investments in PPE | -44.82B | -86.87B | |
| Cash flow Investing Activities | -89.50B | -75.31B | |
| Dividend Paid | -5.85B | -5.63B | |
| Cash flow Financing Activities | 56.89B | 55.92B | |
| Cash at beginning of period | 6.14B | 47.43B | |
| Cash at end of period | 29.98B | 50.41B | |
| Free Cash Flow | 11.63B | -64.50B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Dec-2025